Department of Population Medicine, College of Medicine, Qatar University, Doha, Qatar.
Research School of Population Health, Australian National University, Canberra, Australia; Dr Deb The Travel Doctor, Travel Medicine Alliance, Brisbane, Australia.
Vaccine. 2021 Feb 12;39(7):1044-1050. doi: 10.1016/j.vaccine.2021.01.023. Epub 2021 Jan 18.
There are a myriad of vaccine schedules for rabies pre- (PrEP) and post-exposure prophylaxis (PEP) that differ in the number and timedoses, number of visits, length of schedule, and route of administration. The objective of this study was to systematically review the evidence and investigate how thedifferences in schedules influence titres over time.
Four databaseswere searched from inception to January 2020 for rabies PrEP and PEP studies. Adose-response meta-analysis was utilised to pool geometric mean titres (GMT) over time. Subgroup analyses by route of administration, age group, and schedule were conducted.
80 studies met the inclusion criteria and contributed with 191 datasets and 12,413 participants. Both intradermal (ID) and intramuscular (IM) PrEP/PEP produce adequate GMTs. Significantly lower GMT levels were achieved in older (>50yrs) compared to younger (<50yrs) participants. Short 1-week schedules were as effective as longer schedules that can take between 3 and 12 weeks to complete.
Several effective ID and IM schedules were identified, the selection of a schedule should take into account the patient's needs, costs, availability to return for subsequent doses, and the time required to complete the schedule. Older individuals warrant special attention as they develop lower antibody response.
狂犬病预防接种(PrEP)和暴露后预防(PEP)有许多疫苗接种方案,在接种次数和时间剂量、就诊次数、接种时间和接种途径上存在差异。本研究的目的是系统地回顾相关证据,并探讨这些方案差异如何随时间影响抗体滴度。
从建库到 2020 年 1 月,我们在四个数据库中检索了狂犬病 PrEP 和 PEP 的研究。我们采用剂量反应荟萃分析来汇总随时间变化的几何平均滴度(GMT)。我们还进行了给药途径、年龄组和方案的亚组分析。
80 项研究符合纳入标准,共纳入了 191 项数据集和 12413 名参与者。皮内(ID)和肌肉内(IM)PrEP/PEP 均可产生足够的 GMT。与年龄较轻(<50 岁)的参与者相比,年龄较大(>50 岁)的参与者获得的 GMT 水平显著较低。1 周的短方案与 3-12 周的长方案同样有效。
确定了几种有效的 ID 和 IM 方案,选择方案时应考虑患者的需求、成本、是否有时间返回接受后续剂量以及完成方案所需的时间。由于年龄较大的个体产生的抗体反应较低,因此需要特别注意。